Literature DB >> 9129988

An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line, A549.

A el-Solh1, N M Kumar, M P Nair, S A Schwartz, J S Lwebuga-Mukasa.   

Abstract

Tat (transactivator of transcription) is essential for HIV-1 replication in vivo and in vitro. Tat-(65-80), an RGD containing domain, has been shown to regulate proliferative function of a variety of cell lines, including a human adenocarcinoma cell line, A549. The exact cellular and molecular mechanisms by which these effects are mediated, remain unknown. To evaluate the hypothesis that Tat-(65-80) modulates the expression of immediate early genes (IEG) c-jun, c-myc, c-fos and the tumor suppressor gene p53, serum starved A549 cells were incubated with Tat-(65-80) or heat-inactivated Tat-(65-80) at 10 ng/ml. Total cellular RNA was isolated from the cells at various time points (0-24 hours). In each case, 5 micrograms of RNA was reverse transcribed in 20 microliters of reaction volume. Equal amounts of cDNA were subjected to polymerase chain reaction (PCR) and analyzed by electrophoresis. The photographic negatives of the ethidium bromide stained gels were quantitated by densitometric scanning and normalized to corresponding beta-actin PCR products. Treatment with Tat-(65-80) showed a twofold induction of c-jun at 0.5 h. Peak expression occurred at 60 minutes and remained above baseline at 24 hours (h). c-myc was increased at 0.5 h, reached a twofold increase at 2 h and remained above baseline at 24 h. c-fos increased seven fold at 0.5 h and declined subsequently to baseline at 8 h. p-53 gene was reduced fivefold at 0.5 h and remained downregulated thereafter. These results show that Tat-(65-80) can modulate growth related genes in human lung epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129988     DOI: 10.3109/08820139709022692

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  15 in total

Review 1.  Lung cancer in HIV Infection.

Authors:  Deepthi Mani; Missak Haigentz; David M Aboulafia
Journal:  Clin Lung Cancer       Date:  2011-07-29       Impact factor: 4.785

Review 2.  Mechanisms Underlying HIV-Associated Noninfectious Lung Disease.

Authors:  Rachel M Presti; Sonia C Flores; Brent E Palmer; Jeffrey J Atkinson; Catherine R Lesko; Bryan Lau; Andrew P Fontenot; Jesse Roman; John F McDyer; Homer L Twigg
Journal:  Chest       Date:  2017-04-17       Impact factor: 9.410

Review 3.  Lung cancer: epidemiology, etiology, and prevention.

Authors:  Charles S Dela Cruz; Lynn T Tanoue; Richard A Matthay
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

Review 4.  HIV infection in the etiology of lung cancer: confounding, causality, and consequences.

Authors:  Gregory D Kirk; Christian A Merlo
Journal:  Proc Am Thorac Soc       Date:  2011-06

5.  Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1.

Authors:  E Clark; F Santiago; L Deng; S Chong; C de La Fuente; L Wang; P Fu; D Stein; T Denny; V Lanka; F Mozafari; T Okamoto; F Kashanchi
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 6.  Epidemic of lung cancer in patients with HIV infection.

Authors:  Tiffany A Winstone; S F Paul Man; Mark Hull; Julio S Montaner; Don D Sin
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

Review 7.  Lung cancer in HIV infected patients: facts, questions and challenges.

Authors:  J Cadranel; D Garfield; A Lavolé; M Wislez; B Milleron; C Mayaud
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

8.  9-Aminoacridine inhibition of HIV-1 Tat dependent transcription.

Authors:  Irene Guendel; Lawrence Carpio; Rebecca Easley; Rachel Van Duyne; William Coley; Emmanuel Agbottah; Cynthia Dowd; Fatah Kashanchi; Kylene Kehn-Hall
Journal:  Virol J       Date:  2009-07-24       Impact factor: 4.099

Review 9.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

10.  Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.

Authors:  Mathias Bruyand; Rodolphe Thiébaut; Sylvie Lawson-Ayayi; Pierre Joly; Annie Jeanne Sasco; Patrick Mercié; Jean Luc Pellegrin; Didier Neau; François Dabis; Philippe Morlat; Geneviève Chêne; Fabrice Bonnet
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.